Compare LPSN & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPSN | CING |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.0M | 40.5M |
| IPO Year | 2000 | 2021 |
| Metric | LPSN | CING |
|---|---|---|
| Price | $3.28 | $5.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | 211.4K | ★ 229.8K |
| Earning Date | 03-04-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $257,660,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.94 | $3.20 |
| 52 Week High | $23.55 | $6.74 |
| Indicator | LPSN | CING |
|---|---|---|
| Relative Strength Index (RSI) | 35.40 | 62.79 |
| Support Level | $2.94 | $4.83 |
| Resistance Level | $4.12 | $6.74 |
| Average True Range (ATR) | 0.22 | 0.54 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 29.11 | 45.16 |
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.